Cutaneous Leishmaniasis Drugs Market

Global Cutaneous Leishmaniasis Drugs Market Size, Share & Trends Analysis Report, By Type (Pentavalent Antimonials, Antifungal Drugs, and Anti-Leishmanial/Antimicrobial Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), Forecast (2021-2027)
    Update Available - Forecast 2024-2030   

Published: Jul 2023 | Report Code: OMR2025533 | Category : Pharmaceuticals | Delivery Format: /

The global cutaneous leishmaniasis drugs market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Cutaneous leishmaniasis spreads by the bite of sandflies and primarily affects the skin. Its drugs are generally effective and work well against the parasites causing leishmaniasis. The major factors that are driving the growth of the global cutaneous leishmaniasis drugs market include the growing prevalence of parasitic infections among the global population, ease of direct purchase due to the access to OTC drugs, and the constant innovations and developments of drugs. The prevalence of leishmaniasis is highly subject to environmental factors coupled with natural conditions. Areas with rich vegetation and climatic factors are majorly responsible for the spread of sandflies and the subsequent outbreak of leishmaniasis. For instance, as per the World Health Organization (WHO), it is anticipated that between 600,000 to 1.0 million new global cases of leishmaniasis occur yearly. 

The approved drugs for cutaneous leishmaniasis treatment are majorly fluconazole, impavido, pentam 300 solution, diflucan tablet azole antifungals-systemic, miltefosine capsule, and pentamidine 300 mg solution for injection antiprotozoal agents. However, cutaneous leishmaniasis can be prevented with the support of prophylactic vaccines. The development and consumption of such vaccines support in controlling the disease. Thus, such development is expected to have a positive impact on the overall market growth.

Market Coverage

  • The market number available for – 2020-2027
  • Base year- 2020
  • Forecast period- 2021-2027
  • Segment Covered
  • Regions Covered- Globally

Competitive Landscape:  GlaxoSmithKline plc, Pfizer Inc., and Novartis International AG, among others.

Key questions addressed by the report

  • What is the market growth rate?
  • Which segment and region dominates the market in base year?
  • Which segment and region will project fastest growth in the market?
  • How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

  • Who is the leader in the market?
  • How players are addressing challenges to sustain growth?
  • Where is the investment opportunity?

Global Cutaneous Leishmaniasis Drugs Market Report by Segment

By Type

Pentavalent Antimonials 

Antifungal Drugs 

Anti-Leishmanial/Antimicrobial Drugs

By Distribution Channel

Hospital Pharmacies 

Retail Pharmacies

Online Pharmacies

Global Cutaneous Leishmaniasis Drugs Market by Region

North America

  • United States
  • Canada

Europe

  • UK
  • Germany
  • Italy
  • Spain
  • France
  • Rest of Europe 

Asia-Pacific

  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific 

Rest of the World